Loading clinical trials...
Loading clinical trials...
A Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of LY4006895 in Healthy Volunteers and Patients With Early Symptomatic AD
Conditions
Interventions
LY4006895
Placebo
Locations
9
United States
Collaborative Neuroscience Network - CNS
Los Alamitos, California, United States
K2 Medical Research - The Villages
Lady Lake, Florida, United States
K2 Medical Research
Maitland, Florida, United States
Atlanta Center of Medical Research
Atlanta, Georgia, United States
CenExel iResearch, LLC (CenExel iRA)
Decatur, Georgia, United States
CenExel-HRI
Marlton, New Jersey, United States
Start Date
October 29, 2024
Primary Completion Date
July 1, 2027
Completion Date
July 1, 2027
Last Updated
March 27, 2026
NCT00104325
NCT07388667
NCT03878121
NCT05447416
NCT01399385
NCT07090785
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
1-317-615-4559LillyTrials@Lilly.comPhysicians interested in becoming principal investigators please contact
CONTACT
clinical_inquiry_hub@lilly.comLead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions